Trials / Completed
CompletedNCT04374578
Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes
Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes: A Multi-center Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Glycemic variability will be assessed using continuous glucose monitor(CGM) in type 2 diabetic patients who receive dulaglutide 1.5 mg/qw injection for 4 weeks.
Detailed description
Glycemic fluctuation is a major problem in glucose control in diabetic patients. It is interesting to know that whether weekly GLP-1RA can improve glycemic variability in diabetic patients. The present study aims to assess the effect of dulaglutide on glycemic variability using continuous glucose monitor(CGM) (Libra, Abbott) in type 2 diabetic patients with 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dulaglutide 1.5 MG/ML | Dulaglutide 1.5Mg qw sc injection for 4 weeks |
Timeline
- Start date
- 2020-05-08
- Primary completion
- 2021-01-31
- Completion
- 2021-06-30
- First posted
- 2020-05-05
- Last updated
- 2022-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04374578. Inclusion in this directory is not an endorsement.